A simple ligand-binding assay for thyroxine-binding globulin (TBG) is described. The method depends on the partition of labelled thyroxine between bovine serum albumin and TBG. Differentiation between labelled thyroxine bound to TBG and bovine serum albumin is achieved by the addition of excess TBG antiserum and subsequent precipitation with polyethylene glycol. The results are compared with the Coming Immophase kit method for TBG.
Theory of the method
The reaction of thyroxine with TBG and bovine serum albumin in the same system may be written: This may be re-written: (T4. TBG) = x, x (T4. Alb) x (TBG) which is of the form y = mx + c so that a plot of T4. TBG versus TBG concentration will be linear and pass through the origin.
These conditions may be met by the addition of small quantities of patients' serum to a diluent containing a high concentration of bovine serum albumin. Under these conditions the effect of endogenous albumin and the contributions of other high-capacity, low-affinity, thyroxine-binding proteins such as thyroxine-binding pre-albumin is reduced, and it is predicted that a plot ofTBG bound 421
The usefulness of thyroxine-binding globulin (TBG) assays in conjunction with the measurement of serum thyroxine for the assessment of the thyroid status of patients has been emphasised in several reports. 1 -S It has been shown to provide a more useful assessment of thyroid status than the widely used free thyroxine index (FTI) in cases where TBG levelsare elevated and in cases where thyroxine levels are decreased in chronically and acutely ill patients'<', Several clinically useful assays for TBG have been described. These include radioimmunoassay.s? radial irnmunodiffusion.s rocket immunoelectrophoresis," and competitive ligand-binding assay." 10 Many clinical laboratories involved in thyroid studies are well equipped to carry out radioimmunoassay methods and ligand-binding procedures. The radioimmunoassay of TBG requires the availability of high-purity TBG for iodination. Competitive ligand-binding assays require the use of labelled thyroid hormones which are widely available from several commercial sources at reasonable cost. The availability of monospecific TBG antiserum from commercial sources prepared in a similar manner to that described by Bradwell et al. 8 prompted us to develop a simple ligand-binding assay for TBG. The method outlined is based on the principle described by Mulaisho and Utiger.l" who used T3 antiserum to compete with TBG for the binding of labelled tri-iodothyronine. We have used bovine serum albumin to compete with TBG for labelled thyroxine in our system. Separation of TBG-bound label is effected by polyethylene glycol precipitation of antibody-bound TBG. The principle is similar to the Corning Immophase kit TBG system which makes use of solid-phase coupled TBG antibodies. Dissolve 6·1 g Na 2 HP0 4 and 1·092 g Na H 2 P0 4 .2H 20 in 1 litre distilled water and check that the pH is 7·4. Add 109 BSA to 950 ml phosphate buffer and allow to dissolve. Follow by 1 g bovine gamma globulin and, when dissolved, make up to 1 litre with phosphate buffer. To 100 ml of this buffer/ diluent add 25 !L1 diluted labelled thyroxine solution.
Hall and Laing
This gives a label mass of approximately 0·125 pmol per tube. This mass of tracer is equivalent to less than 10 nrnol/l ofT 4 in a 20!Llpatient serum sample and is thus small compared to the mass of endogenous thyroxine.
ANTISERUM
Dilute the antiserum as supplied by the manufacturers 1 in 10 with 50 mmol/l phosphate buffer, pH 7·4, containing BSA (1 %) and bovine gamma globulin (0·1 %) for use in the procedure.
POLYETHYLENE GLYCOL SOLUTION
Dissolve 180 g polyethylene glycol 6000 in 700 ml distilled water and make up to 1 litre. STANDARDS A pooled, third-trimester pregnancy serum was calibrated in the Corning Immophase TBG assay.
This gave a value of 48·7 ± 0·55 mg/l SEM. For each assay standards of4O·0, 29·2, 24·35,16·2, and 9·74 mgjl were prepared by dilution in 50 mmol/l phosphate buffer.
ASSA Y PROCEDURES
The Corning Immophase TBG assay was carried out according to the manufacturers' instructions. In the assay presented here, 20 !Ll duplicate samples of standard or test were diluted with 500 !Ll buffer/label using an automatic diluter. Diluted antibody (50 !Ll) was added to each tube followed by mixing on a vortex mixer. After incubation at room temperature for at least 10 minutes (time not critical), 1 ml polyethylene glycol solution was added followed by further mixing. The tubes were centrifuged at 2000 g at a temperature of 15°C for 25 minutes, and the supernatants were aspirated. The precipitates were counted and the results calculated from a plot of accumulated counts against TBG concentration.
NON-SPECIFIC BINDING
Non-specific binding was measured by substitution of phosphate buffer for antibody in standard and patient samples.
REPRODUCIBILITY OF ASSAY SYSTEM
A pooled normal human serum was assayed in 14 consecutive assays. It was repeated after every tenth patient sample and, from this, within-and betweenbatch coefficients of variation were computed. A precision profile was calculated from the duplicate means of patient samples in several assays over a range of TBG concentrations.
COMPARISON OF METHODS
A total of 133 samples were assayed (over a wide range of TBG concentrations) by Corning Immophase methodology and the technique presented here. enough to require individual patient non-specific bindings to be taken into account when calculating the results.
STUDY OF ASSAY VARIABLES

Incubation time
The incubation time of four standard curves was varied from 10 minutes to 2 hours.
INCUBA TION TIME
The standard curves produced at incubation times of 10 minutes to 2 hours were virtually superimposable. Incubation times other than these were not studied.
Results
NON-SPECIFIC BINDING
The non-specific binding of 23 patients samples was studied and the mean value was 3·45 ± 0·05 % SEM. This variation was not considered significant When high dilutions of antibody (1 in 80 and 1 in 160) were employed, steep dose response curves were found (Fig. 2 ). In the case of the lower dilution, a marked flattening was observed at higher TBG concentrations. When the higher dilution was employed a biphasic dose response curve was obtained with a significant negative slope at higher TBG concentrations.
REPRODUCIBILITY OF ASSAY SYSTEM
The pooled serum assayed in 14 consecutive assays with the developed assay procedure gave a mean value of 17·6 
Variation in sample size
The sample size employed for the production of standard curves was varied from 10 fl.l to 100 fl.!. A pooled pregnancy serum standard of 60 mgjl was used in this experiment.
Antibody dilution
In addition to the dilution of antibody of 1 in 10, standard curves were set up using dilutions of 1 in 80 and 1 in 160. For this experiment the standard curve was extended to include points of 8· 1, 6·1, and 2·4 rng/l of TBG.
DOSE-RESPONSE CURVE
The assay produced a rectilinear dose response curve (Fig. 1) 
20
The aim of the present study was to develop an assay for TBG which was simple to perform, capable of handling a reasonable sample throughput, relatively inexpensive, and could be set up using readily available reagents. The design of a ligandbinding assay seemed appropriate in that these requirements could be met. In the design of the present system several compromises needed to be reached. According to the theory of the method already discussed, valid assay results are obtained only when the percentage of TBG bound tracer is small. This places constraints on the available steepness of the dose-response curve and predicts that non-linear curves may be expected when the amount of antibody-bound label is high. Experiments carried out with changing sample volumes ( Fig. 4 ) demonstrate that this does occur. The use of smaller sample sizes permits linear dose-response curves to be obtained. The method outlined here produces a linear response up to 50 mgjl, which
In addition to the above comparisons two sera were assayed in which TBG could not be detected. One serum was assayed elsewhere by a Laurell 'rocket' technique and the other by the Corning Immophase method, TBG not being detected in either case.
VARIATION IN SAMPLE SIZE
The results obtained when varying sample size are shown in Figure 4 . Linear dose-response curves were obtained with sample sizes of 10 !ll and 20 !ll, but further increases in sample size, although producing a steeper dose-response curve, gave non-linear standard curves with significant flattening at higher T&G concentrations. From these studies a sample size of 20 !ll was chosen for use. Fig. 3 Within-batch precision profile of the assay system at different analyte concentrations.
COMPARISON OF RESULTS WITH CORNING
IMMOPHASE METHOD
A total of 133 samples were assayed by both methods in the range 13·4-84 mg/I. The regression analysis produced using the Corning method as ordinate gave an equation of y = 0·875x + 3·78. The SD of the slope was ± 0·2, which is significantly different from unity (p <0·05). The intercept was significantly different from zero (P<O·05), and the correlation coefficient was 0·967, indicating good agreement between the methods. coefficient of variation of 4·6 % (mean). From eight consecutive assays, duplicate results of 162 sera were collected, 27 for each ofthe following groups 10-15, 15-20,20-25,25-30, 30-35, and 35 mg/l TBG. The within-batch coefficients of variation for the above ranges of TBG concentrations were found to be 5·65%,2·74%,1·91 %,2·68%,2·79%, and 2·31 % for the means of the duplicate values. A tentative reference range of the method is 14-30 mg/I, The within-batch precision profile is illustrated in Figure 3 .
indicates a reasonable compliance with the method theory. The results of precision studies and profiles indicate that the compromises arrived at enable an assay to be performed which has sufficient precision for clinical use when compared to other assays for TBG based on other principles." 8 A major advantage of the linear standard curve is the ease of calculation of results and the lack of need for curve-fitting procedures. The precision profiles indicate that the assay has a similar precision over a wide range of analyte concentration although some precision is lost at low levels when the percentage of radioactivity bound is very small. This occurs when TBG levels are below the normal range in the present assay.
The within-batch coefficient of variation figures derived from repeated analysis of a single pool and from the profile figures are worthy of comment. The former figure of 4·6% is considerably higher than the latter figures «3 %) except at TBG concentrations of less than 15 mg/1. However the duplicate values are not subject to assay 'drift' as is the former, since the figures are obtained from consecutively processed tubes. Thus the between-batch figures obtained may be capable of being improved further by greater control of manipulative processes such as automated sample handling.
The concentration of antibody used in this type of ligand-binding assay is important. Unlike a conventional competition radioimmunoassay, this reagent must be present in excess. If it is not (Fig. 2 ) a biphasic standard curve may be produced which will cause particular problems at high TBG concentrations. The present assay gives a linear response up to 50 mg/l on the standard curve but linearity to a higher order needs to be achieved for valid results to be obtained at high TBG concentrations. Figure 2 indicates that antibody excess will occur with levels up to 80 mg/l with the present antibody. For this reason all samples reading >50 mg/I must be assayed at increased dilutions.
The problems of accuracy in this type of assay are particularly difficult to assess. There is as yet no internationally recognised standard for TBG. The performance of recovery experiments depends upon the availability of TBG in a pure form with an association constant identical with that of TBG in unextracted serum, as yet unavailable to us. Although the methods under study agree well, there exists nevertheless some systematic difference in the results. This is evidenced by the slope of the regression line and the positive intercept. Such an effect could be explained in terms of the different standard materials used in both assays. Notwithstanding these reser-425 vations, the method seems worthy of a clinical trial' the preliminary results of which (unpublished) indicate that the method has clinical potential. Further studies are indicated to compare this type of assay with TBG assays, based on different principles, carried out on clinically validated patient material. These studies are now in progress in this laboratory.
